AbbVie Inc Stock , ABBV

189.51 +0.41 +0.22%

03:59:59 PM EDT 6/10/2025 BTT

News

On Monday 06/09/2025 the closing price of the AbbVie Inc share was $189.10 on BTT. Compared to the opening price on Monday 06/09/2025 on BTT of $188.80, this is a gain of 0.16%. AbbVie Inc's market capitalization is $275.48 B by 1.77 B shares outstanding.

Is AbbVie stock a Buy, Sell or Hold?

AbbVie stock has received a consensus rating of buy. The average rating score is and is based on 42 buy ratings, 5 hold ratings, and 1 sell ratings.

What was the 52-week low for AbbVie stock?

The low in the last 52 weeks of AbbVie stock was 163.51. According to the current price, AbbVie is 115.90% away from the 52-week low.

What was the 52-week high for AbbVie stock?

The high in the last 52 weeks of AbbVie stock was 218.63. According to the current price, AbbVie is 86.68% away from the 52-week high.

What are analysts forecasts for AbbVie stock?

The 48 analysts offering price forecasts for AbbVie have a median target of 197.85, with a high estimate of 250.00 and a low estimate of 150.00. The median estimate represents a 95.78 difference from the last price of 189.51.

AbbVie Stock Snapshot

184.95

175.00

190.85

13.00

6/10/2025

3:59 PM

0.00

189.10

0.00

334.73 B

1.77 B

163.51

218.63

189.51

6.29

3.54

74.34

99.91

2.39

1.88

10.61

AbbVie News More News

Seeking Alpha 18h

10 dividend stocks to watch ahead of this week's inflation reports

Zacks 21h

Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?

TipRanks 1d

Citi Keeps Their Hold Rating on AbbVie (ABBV)

TipRanks 1d

Bernstein Sticks to Their Hold Rating for AbbVie (ABBV)

TipRanks 1d

Analysts Are Neutral on These Healthcare Stocks: AbbVie (ABBV), Bio-Techne (TECH)

Historical Prices for AbbVie

Loading..
Date	Open	Close	Daily High	Daily Low

Price change over selected period: 0% 0

AbbVie Analyst Data

Total Analysts: 48

Buy Ratings: 42 Neutral Ratings: 5 Sell Ratings: 1

Price *Price Target

Lowest: 150.00 Median: 197.85 Highest: 250.00

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

AbbVie Analyst Opinions

Date	Analyst	Rating	Price
05/14/25	Citigroup Corp.	Downgraded to Hold	$205	neutral
04/29/25	Guggenheim	Maintained Buy	$216	gut
04/28/25	Evercore	Maintained Buy	$205	gut
04/28/25	Morgan Stanley	Maintained Buy	$250	gut
04/22/25	Cantor Fitzgerald	Maintained Buy	$210	gut
04/17/25	Guggenheim	Maintained Buy	$214	gut
04/09/25	Morgan Stanley	Maintained Buy	$241	gut
04/08/25	Goldman Sachs	Maintained Hold	$194	neutral
03/05/25	Wells Fargo & Co	Maintained Buy	$240	gut
03/04/25	Bank of America Merrill Lynch	Maintained Hold	$223	neutral
02/03/25	Citigroup Corp.	Maintained Buy	$215	gut
02/03/25	UBS	Maintained Hold	$190	neutral
02/03/25	Wells Fargo & Co	Maintained Buy	$210	gut
02/03/25	Morgan Stanley	Maintained Buy	$239	gut
02/03/25	Raymond James Financial, Inc.	Maintained Buy	$220	gut
02/03/25	Guggenheim	Maintained Buy	$214	gut
02/03/25	BMO Capital Markets	Maintained Buy	$215	gut
01/28/25	Citigroup Corp.	Maintained Buy	$205	gut
07/26/24	Cantor Fitzgerald	Maintained Buy	$200	gut
07/26/24	Wells Fargo & Co	Maintained Buy	$205	gut
07/26/24	Barclays Capital	Maintained Buy	$200	gut
07/19/24	BMO Capital Markets	Maintained Buy	$214	gut
07/11/24	Morgan Stanley	Maintained Buy	$196	gut
07/09/24	Cantor Fitzgerald	Maintained Buy	$200	gut
07/02/24	Piper Sandler	Maintained Buy	$190	gut
06/20/24	Cantor Fitzgerald	Maintained Buy	$200	gut
06/18/24	Piper Sandler	Maintained Buy	$190	gut
06/05/24	HSBC	Upgraded to Buy	$185	gut
05/17/24	Cantor Fitzgerald	Maintained Buy	$200	gut
04/29/24	Barclays Capital	Maintained Buy	$187	gut
04/29/24	BMO Capital Markets	Maintained Buy	$180	gut
03/27/24	Barclays Capital	Maintained Buy	$195	gut
03/22/24	Guggenheim	Maintained Buy	$190	gut
02/05/24	BMO Capital Markets	Maintained Buy	$195	gut
02/05/24	Raymond James Financial, Inc.	Maintained Buy	$189	gut
02/05/24	Barclays Capital	Maintained Buy	$185	gut
01/29/24	William Blair	Upgraded to Buy		gut
01/23/24	Barclays Capital	Maintained Buy	$175	gut
12/18/23	HSBC	Downgraded to Sell	$156	schlecht
12/11/23	Goldman Sachs	Upgraded to Buy	$173	gut
12/01/23	Raymond James Financial, Inc.	Maintained Buy	$181	gut
11/09/23	Deutsche Bank	Maintained Hold	$150	neutral
10/30/23	Morgan Stanley	Maintained Buy	$196	gut
10/30/23	Barclays Capital	Upgraded to Buy	$170	gut
10/11/23	Morgan Stanley	Maintained Buy	$193	gut
09/29/23	Raymond James Financial, Inc.	Maintained Buy	$177	gut
07/28/23	Piper Sandler	Maintained Buy	$170	gut
07/25/23	William Blair	Maintained Hold		neutral
07/14/23	HSBC	Maintained Buy	$167	gut
07/11/23	Morgan Stanley	Maintained Buy	$182	gut

AbbVie Estimates* in USD

	2025	2026	2027	2028	2029
Revenue	59,850	64,675	69,259	73,954	77,416
Dividend	6.51	6.80	7.13	7.87	3.99
Dividend Yield (in %)	3.44 %	3.59 %	3.77 %	4.16 %	2.11 %
EPS	12.23	13.99	15.48	17.15	18.61
P/E Ratio	15.47	13.51	12.22	11.03	10.16
EBIT	27,960	31,507	34,576	36,823	40,249
EBITDA	28,328	31,866	33,897	37,766	-
Net Profit	21,751	24,769	27,518	30,291	32,736
Net Profit Adjusted	21,751	24,769	27,518	30,291	32,736
Pre-Tax Profit	25,843	29,762	-	36,458	39,001
Pre-Tax Profit Reported	18,034	22,170	25,595	-	39,036
EPS (Non-GAAP) ex. SOE	12.23	13.99	15.48	17.15	18.61
EPS (GAAP)	6.66	9.57	10.76	13.15	15.73
Gross Income	48,116	51,809	55,277	61,454	64,442
Cash Flow from Investing	-4,241	-4,157	-4,343	-1,089	-1,114
Cash Flow from Operations	22,820	27,036	29,822	31,464	31,401
Cash Flow from Financing	-17,219	-15,261	-14,209	-16,797	-18,835
Cash Flow per Share	12.48	14.34	15.75	18.88	20.26
Free Cash Flow	19,542	24,970	27,576	29,647	28,479
Free Cash Flow per Share	9.71	12.48	14.26	17.87	-
Book Value per Share	2.95	6.46	13.10	12.08	18.28
Net Debt	53,958	43,985	31,480	15,847	7,422
Research & Development Exp.	8,863	9,297	9,807	10,242	10,452
Capital Expenditure	-	955	994	1,047	982
Selling, General & Admin. Exp.	14,049	14,708	15,632	14,692	14,728
Shareholder’s Equity	4,744	11,243	22,531	31,066	46,246
Total Assets	132,090	137,142	147,895	153,888	164,577

	Previous Quarter ending 03/31/25	Current Quarter ending 06/30/25	Next Quarter ending 09/30/25	Current Year ending 12/31/25	Next Year ending 12/31/26
Earnings Estimates
No. of Analysts	-	17	17	22	24
Average Estimate	-	3.216 USD	3.223 USD	12.227 USD	13.994 USD
Year Ago	-	0.769 USD	0.877 USD	2.396 USD	-
Publish Date	-	7/25/2025	10/24/2025	-	-
Revenue Estimates
No. of Analysts	-	15	15	23	23
Average Estimate	-	14,951 USD	15,350 USD	59,850 USD	64,675 USD
Year Ago	-	14,462 USD	14,460 USD	56,334 USD	-
Publish Date	-	7/25/2025	10/24/2025	-	-

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Sales	56,334.00	54,318.00	58,054.00	56,197.00	45,804.00	33,266.00	32,753.00
Change of sales in %	3.71	-6.44	3.30	22.69	37.69	1.57	16.08
Gross profit on sales	39,503.00	37,668.00	41,609.00	39,053.00	31,686.00	25,660.00	25,196.00
Gross profit on sales change in %	4.87	-9.47	6.54	23.25	23.48	1.84	17.67
Operating income	16,625.00	18,082.00	22,602.00	19,749.00	15,630.00	13,915.00	12,138.00
Operating income change in %	-8.06	-20.00	14.45	26.35	12.32	14.64	14.39
Income before tax	3,716.00	6,250.00	13,477.00	12,989.00	3,398.00	8,426.00	5,197.00
Income before tax change in %	-40.54	-53.62	3.76	282.25	-59.67	62.13	-32.74
Income after tax	4,238.00	4,820.00	11,782.00	11,468.00	4,556.00	7,842.00	5,657.00
Income after tax change in %	-12.07	-59.09	2.74	151.71	-41.90	38.62	7.08

Balance Sheet in Mio. USD

	2024	2023	2022	2021	2020	2019	2018
Total liabilities	131,797.00	124,314.00	121,518.00	131,093.00	137,468.00	97,287.00	67,798.00
Long-term liabilities per share	52.71	48.97	51.99	54.23	61.64	55.24	34.19
Equity	3,364.00	10,397.00	17,287.00	15,436.00	13,097.00	-8,172.00	-8,446.00
Equity change in %	-67.91	-39.96	11.98	17.83	-	3.24	-265.71
Balance sheet total	135,161.00	134,711.00	138,805.00	146,529.00	150,565.00	89,115.00	59,352.00
Balance sheet total change in %	0.33	-2.95	-5.27	-2.68	68.96	50.15	-16.15

Key Data in USD

	2024	2023	2022	2021	2020	2019	2018
Sales per share	31.77	30.64	32.65	31.62	27.38	22.42	21.19
P/E ratio (year end quote, basic EPS)	74.34	57.00	24.39	20.98	39.35	16.75	25.19
P/E ratio (year end quote, diluted EPS)	74.34	57.00	24.39	20.98	39.35	16.75	25.19
Dividend yield in %	3.54	3.87	3.53	3.92	4.52	4.96	4.28
Equity ratio in %	2.49	7.72	12.45	10.53	8.70	-9.17	-14.23
Debt ratio in %	97.51	92.28	87.55	89.47	91.30	109.17	114.23

AbbVie Insider Activity

Name	Date	shares traded	shares held	Price	type (sell/buy)	option
RAPP EDWARD J	05/08/2025	1,203.00	34,458.00	n/a	Buy	No
BURNSIDE WILLIAM H.L.	05/08/2025	1,203.00	26,958.00	n/a	Buy	No
Alpern Robert J	05/08/2025	1,203.00	35,646.00	n/a	Buy	No
AUSTIN ROXANNE S	05/08/2025	1,203.00	38,458.00	n/a	Buy	No
MEYER MELODY B	05/08/2025	1,203.00	16,498.00	n/a	Buy	No
Davis Jennifer L.	05/08/2025	1,203.00	2,525.00	n/a	Buy	No
Quaggin Susan E	05/08/2025	1,203.00	2,525.00	n/a	Buy	No
GONZALEZ RICHARD A	03/30/2025	2,450.00	386,479.00	n/a	Sell	No
Stewart Jeffrey Ryan	03/30/2025	33,132.00	53,234.00	210.54	Sell	No
Stewart Jeffrey Ryan	03/30/2025	25,700.00	86,366.00	209.49	Sell	No
Stewart Jeffrey Ryan	03/30/2025	25,700.00	112,066.00	79.02	Buy	No
Reents Scott T	03/13/2025	17,644.00	11,577.00	212.34	Sell	No
GONZALEZ RICHARD A	03/02/2025	6,168.00	388,929.00	210.53	Sell	No
RICHMOND TIMOTHY J.	03/02/2025	14,973.00	6,730.00	210.66	Sell	No
RICHMOND TIMOTHY J.	03/02/2025	600.00	6,130.00	211.32	Sell	No
RICHMOND TIMOTHY J.	03/02/2025	5,677.00	21,703.00	209.80	Sell	No
Siatis Perry C	03/02/2025	18,008.00	4,619.00	210.00	Sell	No
Siatis Perry C	03/02/2025	7,775.00	22,627.00	175.28	Buy	No
Siatis Perry C	03/02/2025	7,315.00	14,852.00	149.62	Buy	No
Siatis Perry C	03/02/2025	2,918.00	7,537.00	144.54	Buy	No
GONZALEZ RICHARD A	02/27/2025	73,209.00	487,557.00	205.02	Sell	No
GONZALEZ RICHARD A	02/27/2025	92,460.00	395,097.00	205.11	Sell	No
RICHMOND TIMOTHY J.	02/27/2025	16,904.00	27,380.00	205.02	Sell	No
Michael Robert A.	02/27/2025	27,186.00	132,821.00	205.02	Sell	No
Siatis Perry C	02/27/2025	7,870.00	14,511.00	205.02	Sell	No

AbbVie Dividend Calendar

Date	Name	Dividend	*yield	Currency
2024	AbbVie Inc	6.29	3.54	USD
2023	AbbVie Inc	5.99	3.87	USD
2022	AbbVie Inc	5.71	3.53	USD
2021	AbbVie Inc	5.31	3.92	USD
2020	AbbVie Inc	4.84	4.52	USD
2019	AbbVie Inc	4.39	4.96	USD
2018	AbbVie Inc	3.95	4.28	USD
2017	AbbVie Inc	2.63	2.72	USD
2016	AbbVie Inc	2.35	3.75	USD
2015	AbbVie Inc	2.10	3.54	USD
2014	AbbVie Inc	1.75	2.67	USD
2013	AbbVie Inc	1.60	3.03	USD
2012	AbbVie Inc	0.40	1.17	USD
2011	AbbVie Inc	-	-	USD
2010	AbbVie Inc	-	-	USD
2009	AbbVie Inc	-	-	USD

*Yield of the Respective Date

AbbVie Calendar

Event	Estimate	Info	Date
Earnings Report	3.216 USD	Q2 2025 Earnings Release	07/25/2025
Earnings Report	3.224 USD	Q3 2025 Earnings Release	10/24/2025
Earnings Report	3.367 USD	Q4 2025 Earnings Release	02/04/2026
Earnings Report	2.959 USD	Q1 2026 Earnings Release	04/24/2026

AbbVie Past Events

Event	Actual EPS	Info	Date
Annual General Meeting	2.390 USD	Annual General Meeting	05/09/2025
Earnings Report	0.720 USD	Q1 2025 Earnings Release	04/25/2025
Earnings Report	-0.020 USD	Q4 2024 Earnings Release	01/31/2025
Earnings Report	0.880 USD	Q3 2024 Earnings Release	10/30/2024
Earnings Report	0.770 USD	Q2 2024 Earnings Release	07/25/2024
Annual General Meeting	2.720 USD	Annual General Meeting	05/03/2024
Earnings Report	0.770 USD	Q1 2024 Earnings Release	04/26/2024
Earnings Report	0.460 USD	Q4 2023 Earnings Release	02/02/2024
Earnings Report	1.000 USD	Q3 2023 Earnings Release	10/27/2023
Earnings Report	1.140 USD	Q2 2023 Earnings Release	07/27/2023
Annual General Meeting	6.630 USD	Annual General Meeting	05/05/2023
Earnings Report	0.130 USD	Q1 2023 Earnings Release	04/27/2023
Earnings Report	1.380 USD	Q4 2022 Earnings Release	02/09/2023
Earnings Report	2.210 USD	Q3 2022 Earnings Release	10/28/2022
Earnings Report	0.510 USD	Q2 2022 Earnings Release	07/29/2022
Annual General Meeting	6.450 USD	Annual General Meeting	05/06/2022
Earnings Report	2.510 USD	Q1 2022 Earnings Release	04/29/2022
Earnings Report	2.260 USD	Q4 2021 Earnings Release	02/02/2022

AbbVie Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Moody’s Daily Credit Risk Score

Risk

Low
Medium
High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

AbbVie Management

Name	Job
Sanjay Narayan	Chief Ethics & Compliance Officer, Senior VP
Robert A. Michael	Chief Executive Officer & Director
Scott T. Reents	Chief Financial Officer & Executive Vice President
Timothy J. Richmond	Chief Human Resources Officer & Executive VP
Azita Saleki-Gerhardt	Chief Operations Officer & Executive VP
Roopal Thakkar	Chief Scientific Officer, Executive VP-R&D
Richard A. Gonzalez	Executive Chairman
Nicholas Donoghoe	Executive VP, Chief Business & Strategy Officer
Jennifer L. Davis	Independent Director
Robert J. Alpern	Independent Director
Rebecca Brown Roberts	Independent Director
Susan E. Quaggin	Independent Director
Thomas C. Freyman	Independent Director
Brett J. Hart	Independent Director
William H. L. Burnside	Independent Director
Edward J. Rapp	Independent Director
Frederick H. Waddell	Independent Director
Glenn Fletcher Tilton	Independent Director
Thomas J. Falk	Independent Director
Melody B. Meyer	Independent Non-Executive Director
Roxanne Schuh Austin	Lead Independent Director
Latif Akintade	SVP-Medical Affairs & Health Economics
Perry C. Siatis	Secretary, Executive VP & General Counsel
Carrie Strom	Senior VP & President-Global Allergan Aesthetics
David R. Purdue	Senior Vice President & Controller
Gregory Miley	Senior Vice President-Government Affairs
Liz Shea	Senior Vice President-Investor Relations
Brian L. Durkin	Vice President
Esteban Plata	Vice President-Western Europe & Canada